Publications by authors named "Ludwig Merker"

Claim this Profile
N
Nephropathy in Diabetes.
Ludwig Merker, Thomas Ebert, Erwin Schleicher, Berend Isermann, Martina Guthoff

Exp Clin Endocrinol Diabetes· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry.
Stephan Kress, Peter Bramlage, Reinhard W Holl, Christian Dominik Möller, Steffen Mühldorfer, Ludwig Merker

Diabetes Obes Metab· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nephropathy in Diabetes.
Ludwig Merker, Thomas Ebert, Martina Guthoff, Berend Isermann

Exp Clin Endocrinol Diabetes· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nephropathy in Diabetes.
Ludwig Merker, Bernd-Walter Bautsch, Thomas Ebert, Martina Guthoff, Berend Isermann

Exp Clin Endocrinol Diabetes· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Nephropathy in diabetes].
Ludwig Merker

MMW Fortschr Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany.
Lutz Heinemann, Patricia Kaiser, Guido Freckmann, Denis Grote-Koska, Wolfgang Kerner, Ludwig Merker

Horm Metab Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany.
Lutz Heinemann, Patricia Kaiser, Guido Freckmann, Denis Grote-Koska, Wolfgang Kerner, Ludwig Merker

Horm Metab Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali

Cardiovasc Diabetol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Hans-Ulrich Haering, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali

Diabetes Res Clin Pract· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux

Clin Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).
Javier Morales, Ludwig Merker

Adv Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke

Diabetes Care· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke

Diabetes Care· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker

Lancet· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis